Investing.com -- Roche Holding AG (SIX:RO) announced positive Phase III results for its giredestrant treatment, which significantly improved progression-free survival in patients with ER-positive advanced breast cancer.
The pharmaceutical company reported that the EVERA study met its co-primary endpoints when giredestrant was used in combination with everolimus.
The data from this successful clinical trial will be presented at an upcoming medical meeting, though specific details about the timing and venue were not disclosed.
This development represents an important advancement in treatment options for patients with estrogen receptor-positive advanced breast cancer, a common form of the disease.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.